Form D · Biotechnology
Helaina Inc
New York, NY · CIK 0001786488
Offering snapshot reported Aug 31, 2020 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Aug 19, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 31, 2020 | Initial | $3,999,998 | No comparison | 6 | SEC filing |
| Feb 11, 2020 | Initial | $360,000 | No comparison | 4 | SEC filing |
| Aug 27, 2019 | Initial | $50,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-374471
Source: Form D, filed Aug 31, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Laura H Katz | Director, Executive |
| Kevin Thau | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
180 Varick Street 6th Floor
New York, NY, 10014
New York, NY, 10014